Lumos Diagnostics Holdings Ltd
OTC:LDXHF
Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
CLIA waiver: Management reiterated expectation of a CLIA waiver grant from the FDA this month (March), calling it the company’s most significant near-term milestone and a trigger for broader U.S. commercialization.
Commercial deal: Lumos signed a 6‑year exclusive U.S. distribution agreement with PHASE Scientific that management says guarantees a minimum of USD 317,000,000 in sales to Lumos over the term.
Reimbursement: FebriDx has an established reimbursement rate of USD 41.38 per test from CMS/MACs, which management highlighted as critical to adoption.
H1 results: First half revenue was USD 6.1 million, gross profit USD 4.2 million, gross margin 68%, and adjusted EBITDA loss of USD 1.4 million — in line with management’s expectations.
Cash & funding: Operating cash flow was positive at USD 0.1 million in H1; Lumos received USD 2.8 million of BARDA funding in the half and has a financing facility with USD 1.0 million drawn and USD 4.0 million remaining.
Pediatric study: Lumos secured approximately USD 6.2 million to fund a pediatric trial (ages 2–12); management expects that trial to complete near the end of the calendar year.
Manufacturing & capacity: Management said current capacity should meet expected PHASE demand for the first two years of the agreement, with possible capacity investments needed thereafter.
Pipeline: A women’s health product is at feasibility stage; management estimates diagnostic development to market typically takes about 2–3 years if moved into development.
